Olympia Launches Polidocanol Injection Across 49 States

Compounded injectable portfolios at 503B outsourcing facilities are expanding into aesthetics at a measurable pace, and Olympia Pharmaceuticals has added another data point: a Polidocanol 2% (20 mg/mL) injection, now available for clinical office use across 49 states. For QA directors and regulatory leads at competing outsourcing facilities, the move signals continued pressure to broaden specialty compounded offerings while sustaining FDA quality standards under the 503B framework.

The formulation is supplied in a 30 mL volume for intravenous administration and functions as a non-ionic detergent sclerosant, damaging the vein endothelium to induce vessel collapse and gradual reabsorption. Its secondary local anesthetic properties reduce procedural discomfort, a characteristic that supports standardized clinical protocols in dermatology and cosmetic vein care settings. The ready-to-use presentation is intended to reduce procedure prep time for qualified healthcare professionals.

From a compliance standpoint, Olympia operates as both an FDA-registered 503B outsourcing facility and a 503A pharmacy, positioning it to supply office-use compounded medications without patient-specific prescriptions where state law permits. Distribution across 49 states reflects the regulatory complexity 503B facilities navigate: each state imposes its own receipt and dispensing requirements on top of federal GMP obligations under 21 CFR Part 211 and USP standards applicable to sterile compounding.

The 2% concentration standardizes dosing across routine aesthetic appointments, a detail relevant to practices building repeatable, protocol-driven vein care programs. Pharmacist Christopher Lorich, PharmD, noted in the company's release that formulation consistency is critical for clinical protocols in targeted vein care, a position that aligns with process validation expectations for compounded sterile preparations.

Olympia's broader portfolio spans weight loss, IV nutritional therapy, erectile dysfunction, and dermatology, suggesting a deliberate strategy to consolidate specialty compounded supply across high-demand aesthetic and clinical categories under a single 503B source. For plant heads evaluating outsourcing partnerships or competitive positioning, the 49-state distribution footprint and ready-to-use format represent the operational benchmark Olympia is setting in this segment.

The commercial availability of Polidocanol 2% injection will test whether consistent sterility assurance and state-by-state distribution compliance can scale alongside rising demand for compounded aesthetics formulations.

Source: Olympia Pharmaceuticals via GlobeNewswire, August 25, 2026.